EGFR and lung cancer: Administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) to patients with activating mutations in the EGFR gene, especially exon 19 deletions and exon 21 p.L858R point mutations, has significantly improved treatment and outcome of advanced-stage lung cancer patients [2].